Shanghai Fosun Pharmaceut... (SFOSF)
Shanghai Fosun Pharmaceutical () Statistics
Share Statistics
Shanghai Fosun Pharmaceutical () has 4.27B shares outstanding. The number of shares has increased by -5% in one year.
| Shares Outstanding | 4.27B |
| Shares Change (YoY) | -5% |
| Shares Change (QoQ) | -7.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.67B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 12.63 and the forward PE ratio is null. Shanghai Fosun Pharmaceutical ()'s PEG ratio is 0.75.
| PE Ratio | 12.63 |
| Forward PE | n/a |
| PS Ratio | 0.85 |
| Forward PS | n/a |
| PB Ratio | 0.74 |
| P/FCF Ratio | 523.89 |
| PEG Ratio | 0.75 |
Enterprise Valuation
Shanghai Fosun Pharmaceutical () has an Enterprise Value (EV) of 53.16B.
| EV / Sales | 1.29 |
| EV / EBITDA | 6.18 |
| EV / EBIT | 11.87 |
| EV / FCF | 795.98 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.67.
| Current Ratio | 0.92 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.68 |
| Debt / FCF | 474.57 |
| Interest Coverage | 2.96 |
Financial Efficiency
Return on Equity is 5.86% and Return on Invested Capital is 3.62%.
| Return on Equity | 5.86% |
| Return on Assets | 2.36% |
| Return on Invested Capital | 3.62% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $68.3K |
| Employee Count | 40,557 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.94 |
Taxes
| Income Tax | 656.84M |
| Effective Tax Rate | 15.75% |
Stock Price Statistics
The stock price has increased by 27.45% in the last 52 weeks. The beta is 1.13, so Shanghai Fosun Pharmaceutical ()'s price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | 27.45% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 62.72 |
| Average Volume (20 Days) | 820 |
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical () had revenue of 41.07B and earned 2.77B in profits. Earnings per share was 1.04.
| Revenue | 41.07B |
| Gross Profit | 19.7B |
| Operating Income | 4.25B |
| Net Income | 2.77B |
| EBITDA | 8.6B |
| EBIT | 5.6B |
| Earnings Per Share (EPS) | 1.04 |
Balance Sheet
The company has 13.52B in cash and 31.7B in debt, giving a net cash position of -18.17B.
| Cash & Cash Equivalents | 13.52B |
| Total Debt | 31.7B |
| Net Cash | -18.17B |
| Retained Earnings | 26.55B |
| Total Assets | 117.46B |
| Working Capital | -2.96B |
Cash Flow
In the last 12 months, operating cash flow was 4.48B and capital expenditures -4.41B, giving a free cash flow of 66.79M.
| Operating Cash Flow | 4.48B |
| Capital Expenditures | -4.41B |
| Free Cash Flow | 66.79M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 47.97%, with operating and profit margins of 10.34% and 6.74%.
| Gross Margin | 47.97% |
| Operating Margin | 10.34% |
| Pretax Margin | 10.15% |
| Profit Margin | 6.74% |
| EBITDA Margin | 20.95% |
| EBIT Margin | 10.34% |
| FCF Margin | 0.16% |
Dividends & Yields
SFOSF pays an annual dividend of $0.1, which amounts to a dividend yield of 2.37%.
| Dividend Per Share | $0.10 |
| Dividend Yield | 2.37% |
| Dividend Growth (YoY) | -34.85% |
| Payout Ratio | 69.56% |
| Earnings Yield | 7.92% |
| FCF Yield | 0.19% |
Analyst Forecast
Currently there are no analyst rating for SFOSF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.84 |
| Piotroski F-Score | 7 |